Entering text into the input field will update the search result below

Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Jun. 03, 2020 4:39 AM ETCompugen Ltd. (CGEN)ABMD, LLY1 Comment


  • Compugen's triple therapy for solid tumors is cleared for IND.
  • Abiomed's heart pump for COVID-19 receives emergency authorization.
  • Eli Lilly's cyramza gets another expanded label.
  • Looking for more stock ideas like this one? Get them exclusively at The Total Pharma Tracker. Get started today »

Compugen Received FDA Clearance of IND Application

Compugen (NASDAQ:CGEN) announced that the FDA has given its clearance for the Investigational New Drug for Phase 1/2 study of its Triple combination therapy for cancer. The company expects to initiate the trial during the second half of the year. The trial is expected to provide a push to the company’s DNAM axis hypothesis as well as to biomarker based approach for treating advanced solid tumors.

Compugen reported that it plans to start an open-label Phase 1/2 trial under this IND. The trial will aim to assess the safety, tolerability and preliminary antitumor activity of COM701 in conjunction with Opdivo® and BMS-986207. Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "The encouraging clinical data from the ongoing COM701 Phase 1 study evaluating our discovered target PVRIG, and the emerging clinical validation of the TIGIT pathway, leave us increasingly enthusiastic about our science-driven clinical approach evaluating these two complementary yet distinct pathways in combination with PD-1.” Bristol Myers Squibb has already determined the dose levels for Opdivo® and BMS-986207 combinations in prior testing.

COM701 is a humanized antibody and works by binding with PVRIG and blocking the interaction with PVRL2. Preclinical data has demonstrated that control of PVRIG may trigger a strong anti-tumor immune response. It has also shown to have synergistic impact when taken in combination with inhibitors of TIGIT and/or PD-1. Currently, the drug candidate is being tested in a Phase 1 clinical trial. It has shown positive safety profile and the potential of anti-tumor activities.

COM701 has been tested as a monotherapy as well and provided partial response. It has also been assessed in combination with nivolumab for patients suffering from difficult to treat cancers. The company is working on the premises that PVRIG and PD-1 are two distinct pathways and controlling them

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we’ve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

This article was written by

Avisol Capital Partners profile picture

Avisol Capital Partners is made up of a team of medical experts, finance professionals and techies, all of whom invest their own money in the picks they share. They aim to help readers find the middle ground between value and growth investing, as they demystify the biopharma industry.

They lead the investing group Total Pharma Tracker where they offer a monthly updated catalyst database, an investability scoring system for quick reference ideas, and direct access in chat for dialogue and questions. Learn more.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (1)

Compugen gain is over 300% fiscal year
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.